Molecular Studies and Clinical Correlations in Human Prostatic Disease
1 other identifier
observational
5,290
1 country
1
Brief Summary
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 1990
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 1990
CompletedFirst Submitted
Initial submission to the registry
December 19, 2007
CompletedFirst Posted
Study publicly available on registry
December 21, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
March 9, 2026
March 1, 2026
36.7 years
December 19, 2007
March 6, 2026
Conditions
Keywords
Eligibility Criteria
All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.
You may qualify if:
- Men with prostate conditions representing the following disease states:
- No Cancer Diagnosis
- Clinically Localized Disease
- Rising PSA
- Clinical Metastases: Noncastrate
- Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
- Signed informed consent
You may not qualify if:
- Patients without any prostate related problems.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Memorial Sloan Kettering Cancer Centerlead
- Rockefeller Universitycollaborator
- Flinders Medical Centrecollaborator
- University of Southern Californiacollaborator
- Gen-Probe, Incorporatedcollaborator
- Genentech, Inc.collaborator
- General Electriccollaborator
- Purdue Universitycollaborator
- Biocept, Inc.collaborator
- Duke Universitycollaborator
- Ikonysiscollaborator
- Array Genomicscollaborator
- Cold Spring Harbor Laboratorycollaborator
- Nodalitycollaborator
- Epic Sciencescollaborator
- Rutgers Cancer Institute of New Jerseycollaborator
- Dana-Farber Cancer Institutecollaborator
- Johns Hopkins Universitycollaborator
- M.D. Anderson Cancer Centercollaborator
- Oregon Health and Science Universitycollaborator
- University of California, San Franciscocollaborator
- University of Chicagocollaborator
- University of Michigancollaborator
- University of Washingtoncollaborator
- University of Wisconsin, Madisoncollaborator
- Fred Hutchinson Cancer Centercollaborator
- Broad Institute of MIT and Harvardcollaborator
- Weill Medical College of Cornell Universitycollaborator
- Institute of Cancer Research, United Kingdomcollaborator
- Vitatex Inc.collaborator
- Serametrix Corporationcollaborator
- Promega Corporationcollaborator
- Creatv Microtech, Inc.collaborator
- Viatar LLCcollaborator
- Massachusetts Institute of Technologycollaborator
- Advanced Cell Diagnosticscollaborator
- ApoCell, Inc.collaborator
- Beckman Coulter GmbHcollaborator
- Bioview, Inc.collaborator
- Clearbridge BioMedics Pte Ltd., Singaporecollaborator
- Cynvenio Biosystemscollaborator
- Exosome Diagnostics, Inc.collaborator
- Fluxion Biosciencescollaborator
- Foundation Medicinecollaborator
- Universitätsklinikum Hamburg-Eppendorfcollaborator
- Brooklyn ImmunoTherapeutics, LLCcollaborator
- Ohio State Universitycollaborator
- Palo Alto Research Centercollaborator
- Rarecellscollaborator
- Silicon Biosystemscollaborator
- The Scripps Research Institutecollaborator
- University of Minnesotacollaborator
- Janssen Diagnostics, LLCcollaborator
- University of Regensburgcollaborator
- Innocrin Pharmaceuticals Inc.collaborator
Study Sites (1)
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Related Links
Biospecimen
Human tissue, body fluids, and blood Fresh tissue will be obtained from patients undergoing a biopsy or surgical procedure as part of their standard therapy or as part of an investigational research protocol. Previously stored pathology specimens may also be used. Peripheral blood, bone marrow, urine, and other bodily fluids and samples will also be obtained as needed.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Susan Slovin, MD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 19, 2007
First Posted
December 21, 2007
Study Start
April 1, 1990
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
March 9, 2026
Record last verified: 2026-03